{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lynn T"],"funding":["NIDA NIH HHS","Burroughs Wellcome Fund","National Institutes of Health","National Institute on Drug Abuse"],"pagination":["104445"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11890952"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["168"],"pubmed_abstract":["Opioid-use disorder (OUD) during pregnancy has increased in the United States to critical levels and is a leading cause of maternal morbidity and mortality. Untreated OUD is associated with pregnancy complications in particular, preterm birth. Medications for OUD, such as buprenorphine, are recommended with the added benefit that treatment during pregnancy increases treatment post-partum. However, the rate of preterm birth in individuals using illicit opioids or being treated with opioid agonist therapeutics is double that of the general population. Since inflammation in the placenta and the associated fetal membranes (FM) is a common underlying cause of preterm birth, we sought to determine if the opioid, buprenorphine, induces sterile inflammation in human FMs and to examine the mechanis"],"journal":["Journal of reproductive immunology"],"pubmed_title":["Buprenorphine induces human fetal membrane sterile inflammation."],"pmcid":["PMC11890952"],"funding_grant_id":["R01DA051390","R01DA062540","R01 DA051390","R01 DA062540","NPG125"],"pubmed_authors":["Abrahams VM","Kelleher ME","Yonkers KA","Lynn T","Logan RW","Georges HM","McCauley EM"],"additional_accession":[]},"is_claimable":false,"name":"Buprenorphine induces human fetal membrane sterile inflammation.","description":"Opioid-use disorder (OUD) during pregnancy has increased in the United States to critical levels and is a leading cause of maternal morbidity and mortality. Untreated OUD is associated with pregnancy complications in particular, preterm birth. Medications for OUD, such as buprenorphine, are recommended with the added benefit that treatment during pregnancy increases treatment post-partum. However, the rate of preterm birth in individuals using illicit opioids or being treated with opioid agonist therapeutics is double that of the general population. Since inflammation in the placenta and the associated fetal membranes (FM) is a common underlying cause of preterm birth, we sought to determine if the opioid, buprenorphine, induces sterile inflammation in human FMs and to examine the mechanis","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-07-16T23:37:42.093Z","creation":"2026-07-12T03:11:32.583Z"},"accession":"S-EPMC11890952","cross_references":{"pubmed":["39914058"],"doi":["10.1016/j.jri.2025.104445"]}}